Evidence
November 4, 2022Population Health Video
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
October 18, 2022Clinical Outcomes Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
EDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
September 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
October 18, 2022Clinical Outcomes Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
EDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
October 18, 2022Clinical Outcomes Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
EDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
ManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
October 18, 2022Clinical Outcomes Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
EDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
ManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE ExpiredEDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
October 3, 2022Population Health Article / Publication
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn MoreADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
September 23, 2022Clinical Outcomes Conference Updates
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
Learn MoreSeptember 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
ADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
September 23, 2022CGM Technology and Digital Health CGM Best Practices / Interview
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Short on time? Click here for an abbreviated version.
September 15, 2022CGM Technology and Digital Health CE Activities
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
Learn More
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CME INFORMATION
Release Date: 9/15/2022
Expiration Date: 9/15/2023
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
September 11, 2022CGM Technology and Digital Health Article / Publication
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More